Molecular Partners AG (MOLN)
Automate Your Wheel Strategy on MOLN
With Tiblio's Option Bot, you can configure your own wheel strategy including MOLN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MOLN
- Rev/Share 0.146
- Book/Share 4.1618
- PB 0.7072
- Debt/Equity 0.0173
- CurrentRatio 14.3051
- ROIC -0.4152
- MktCap 108527949.2557
- FreeCF/Share -1.6899
- PFCF -1.8871
- PE -1.8534
- Debt/Assets 0.0154
- DivYield 0
- ROE -0.3576
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 2
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Molecular Partners to Present at Upcoming Investor Conferences
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in two upcoming investor conferences.
Read More
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
Published: April 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority.
Read More
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
After losing some value lately, a hammer chart pattern has been formed for Molecular Partners AG Sponsored ADR (MOLN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Read More
Molecular Partners Publishes Invitation to Annual General Meeting 2025
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2025.
Read More
Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript
Published: March 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Molecular Partners AG (NASDAQ:MOLN ) Q4 2024 Earnings Conference Call March 7, 2025 8:00 AM ET Company Participants Michael Tobias Stumpp - EVP Projects Patrick Amstutz - Co-Founder & CEO Philippe Legenne - Chief Medical Officer Robert Hendriks - SVP Finance Seth Lewis - SVP Investor Relations, Communications and Strategy Conference Call Participants Jonathan Chang - Leerink Partners Richard Vosser - JPMorgan Michael Nedelcovych - TD Cowen Joris Zimmermann - Octavian Operator Good morning, and welcome to the Molecular Partners Fourth Quarter and Full Year 2024 Results Call. All participants will be in listen-only mode.
Read More
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences.
Read More
About Molecular Partners AG (MOLN)
- IPO Date 2021-06-16
- Website https://www.molecularpartners.com
- Industry Biotechnology
- CEO Dr. Patrick Amstutz Ph.D.
- Employees 158